Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

UK-based pharma major AstraZeneca and its Japanese partner Daiichi Sankyo are moving to expand the reach of their blockbuster ...

Global pharmaceutical stocks dropped sharply Monday after former U.S. President Donald Trump pledged to cut prescription drug ...